EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols.

abstract：:ET is a chronic myeloproliferative disorder rarely evolving into AML, sometimes preceded by a myelodysplastic syndrome (MDS). Such transformations mostly occur in patients treated with radiophosphorous ((32)P) or alkylating agents, especially busulfan. Recently, concern has also arisen about the long-term safety of hy...

journal_title：Leukemia

authors： Bernasconi P,Boni M,Cavigliano PM,Calatroni S,Brusamolino E,Passamonti F,Volpe G,Pistorio A,Giardini I,Rocca B,Caresana M,Lazzarino M,Bernasconi C

更新日期：2002-10-01 00:00:00

abstract：:Chimeric antigen receptor (CAR)-T-cell is a safe and effective therapy of B-cell cancers but it is unknown if this is so in persons with prior hepatitis B virus (HBV) infection. We studied 70 subjects with advanced B-cell cancers receiving CAR-T-cell therapy, 12 of whom had chronic HBV-infection (HBsAg positive) and 2...

journal_title：Leukemia

authors： Wang Y,Liu Y,Tan X,Pan B,Ge J,Qi K,Cheng H,Cao J,Shi M,Yan Z,Qiao J,Jing G,Wang X,Sang W,Xia R,Zhang X,Li Z,Gale RP,Zheng J,Zhu F,Xu K

更新日期：2020-10-01 00:00:00

abstract：:Tumor lysis syndrome (TLS) has been described in over 40% of patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. We conducted a retrospective analysis to determine predictive factors for TLS. In 116 patients, the incidence of TLS was 46% (95% CI: 36-55%). In uni...

journal_title：Leukemia

authors： Blum KA,Ruppert AS,Woyach JA,Jones JA,Andritsos L,Flynn JM,Rovin B,Villalona-Calero M,Ji J,Phelps M,Johnson AJ,Grever MR,Byrd JC

更新日期：2011-09-01 00:00:00

abstract：:Hematopoiesis is orchestrated by interactions between hematopoietic stem/progenitor cells (HSPCs) and stromal cells within bone marrow (BM) niches. Side population (SP) functionality is a major characteristic of HSPCs related to quiescence and resistance to drugs and environmental stresses. At steady state, SP cells a...

journal_title：Leukemia

authors： Malfuson JV,Boutin L,Clay D,Thépenier C,Desterke C,Torossian F,Guerton B,Anginot A,de Revel T,Lataillade JJ,Le Bousse-Kerdilès MC

更新日期：2014-04-01 00:00:00

abstract：:The long-term results in 130 patients with newly diagnosed acute myelogenous leukemia treated with continuous infusion high-dose ara-C (1.5 gm/m2/day x 4 days, CIHDAC) were compared with those in 264 patients treated in previous studies with standard dose ara-C (70-90 mg/m2/d x 7 days) plus either adriamycin (Ad-OAP),...

journal_title：Leukemia

authors： Ghaddar HM,Plunkett W,Kantarjian HM,Pierce S,Freireich EJ,Keating MJ,Estey EH

更新日期：1994-08-01 00:00:00

abstract：:In this study, we compared immunoglobulin heavy-chain-gene-based minimal residual disease (MRD) detection by real-time quantitative PCR (RQ-PCR) and next-generation sequencing (NGS) to assess whether NGS could overcome some limitations of RQ-PCR and further increase sensitivity, specificity, accuracy and reproducibili...

journal_title：Leukemia

authors： Ladetto M,Brüggemann M,Monitillo L,Ferrero S,Pepin F,Drandi D,Barbero D,Palumbo A,Passera R,Boccadoro M,Ritgen M,Gökbuget N,Zheng J,Carlton V,Trautmann H,Faham M,Pott C

更新日期：2014-06-01 00:00:00

abstract：:Anaplastic large cell lymphoma (ALCL) expressing the CD30 antigen is an uncommon subtype of non-Hodgkin's lymphoma characterized by distinct morphological and clinical features. The recurrent chromosomal abnormality found in these tumours is a t(2;5)(p23;q35) which has been detected in a minority of these cases, predo...

journal_title：Leukemia

authors： Wlodarska I,De Wolf-Peeters C,Michaux L,Mecucci C,Verhoef G,Cassiman JJ,Van den Berghe H

更新日期：1995-10-01 00:00:00

abstract：:In order to improve leukemia-free survival (LFS) without the treatment-related morbidity of allogeneic bone marrow transplantation or multiple prolonged cycles of consolidation chemotherapy, we evaluated the long-term outcome of autologous transplantation of peripheral blood progenitor cells (PBPCs) as postremission t...

journal_title：Leukemia

authors： Collisson EA,Lashkari A,Malone R,Paquette R,Emmanouilides C,Territo MC,Schiller GJ

更新日期：2003-11-01 00:00:00

abstract：:The fms-related tyrosine kinase 3 (FLT3) receptor has been extensively studied over the past two decades with regard to oncogenic alterations that do not only serve as prognostic markers but also as therapeutic targets in acute myeloid leukemia (AML). Internal tandem duplications (ITDs) became of special interest in t...

journal_title：Leukemia

authors： Reiter K,Polzer H,Krupka C,Maiser A,Vick B,Rothenberg-Thurley M,Metzeler KH,Dörfel D,Salih HR,Jung G,Nößner E,Jeremias I,Hiddemann W,Leonhardt H,Spiekermann K,Subklewe M,Greif PA

更新日期：2018-02-01 00:00:00

abstract：:Mitoxantrone is a synthetic aminoanthraquinone we have previously reported to be effective for patients with acute leukemia in relapse. We presently report the results of a trial of mitoxantrone in combination with cytosine arabinoside (ara-C) in patients with refractory or relapsed acute myelocytic leukemia (AML). Fo...

journal_title：Leukemia

authors： Paciucci PA,Dutcher JP,Cuttner J,Strauman JJ,Wiernik PH,Holland JF

更新日期：1987-07-01 00:00:00

abstract：:Neomorphic mutations in isocitrate dehydrogenase 1 (IDH1) are frequently found in several human cancer types including acute myeloid leukemia (AML) and lead to the production of high levels of the oncometabolite (R)-2-hydroxyglutarate (R-2HG). Here we report the characterization of BAY1436032, a novel pan-mutant IDH1 ...

journal_title：Leukemia

authors： Chaturvedi A,Herbst L,Pusch S,Klett L,Goparaju R,Stichel D,Kaulfuss S,Panknin O,Zimmermann K,Toschi L,Neuhaus R,Haegebarth A,Rehwinkel H,Hess-Stumpp H,Bauser M,Bochtler T,Struys EA,Sharma A,Bakkali A,Geffers R,Ara

更新日期：2017-10-01 00:00:00

abstract：:Minimal residual disease (MRD) is a powerful prognostic factor in acute lymphoblastic leukemia (ALL) and is used for patient stratification and treatment decisions, but its precise role in Philadelphia chromosome positive ALL is less clear. This uncertainty results largely from methodological differences relating to t...

journal_title：Leukemia

authors： Pfeifer H,Cazzaniga G,van der Velden VHJ,Cayuela JM,Schäfer B,Spinelli O,Akiki S,Avigad S,Bendit I,Borg K,Cavé H,Elia L,Reshmi SC,Gerrard G,Hayette S,Hermanson M,Juh A,Jurcek T,Chillón MC,Homburg C,Martinelli G,

更新日期：2019-08-01 00:00:00

abstract：:Blockade of tumor necrosis factor (TNF)alpha by a soluble TNF receptor fusion protein (etanercept; Enbrel) improved in vitro hemopoiesis from the marrow of patients with myelodysplastic syndrome (MDS). Therefore, we enrolled 14 MDS patients (4 RA, 2 RARS, 6 RAEB, 2 CMML), 44-80 (median 60) years old, in a pilot trial....

journal_title：Leukemia

authors： Deeg HJ,Gotlib J,Beckham C,Dugan K,Holmberg L,Schubert M,Appelbaum F,Greenberg P

更新日期：2002-02-01 00:00:00

abstract：:A patient with Philadelphia positive (Ph'+) acute lymphoblastic leukemia (ALL), in remission for over 4 years, developed an acute myeloblastic leukemia (AML), M2-type. During the second disease, the blast cells displayed a typical t(8;21)(q22;q22) translocation, in the absence of the Ph' chromosome. This is the first ...

journal_title：Leukemia

authors： De Cuia MR,Alimena G,Gastaldi R,Spiriti MA,Giona F,Mancini M,Mandelli F

更新日期：1989-04-01 00:00:00

abstract：:We looked for bcl-2 protein expression by immunocytochemistry on bone marrow slides from 51 cases of myelodysplastic syndrome (MDS), of whom 25 received some form of chemotherapy. Forty-six of them had at least 20% bcl-2 positive blasts and the median percentage of positive blasts was 80%, whereas myeloid cells beyond...

journal_title：Leukemia

authors： Lepelley P,Soenen V,Preudhomme C,Merlat A,Cosson A,Fenaux P

更新日期：1995-04-01 00:00:00

abstract：:Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare disease that currently lacks genomic and genetic biomarkers to assist in its clinical management. We performed whole-exome sequencing (WES) of three BPDCN cases. Based on these data, we designed a resequencing approach to identify mutations in 38 sele...

journal_title：Leukemia

authors： Menezes J,Acquadro F,Wiseman M,Gómez-López G,Salgado RN,Talavera-Casañas JG,Buño I,Cervera JV,Montes-Moreno S,Hernández-Rivas JM,Ayala R,Calasanz MJ,Larrayoz MJ,Brichs LF,Gonzalez-Vicent M,Pisano DG,Piris MA,Álvarez S,

更新日期：2014-04-01 00:00:00

abstract：:Patients with normal-karyotype acute myelogenous leukemia (NKAML) may have undetected genetic abnormalities that could affect prognosis. Screening for known AML-specific genetic abnormalities using the reverse transcription polymerase chain reaction (RT-PCR) may help in arriving at a more definitive prognosis. To test...

journal_title：Leukemia

authors： Sarriera JE,Albitar M,Estrov Z,Gidel C,Aboul-Nasr R,Manshouri T,Kornblau S,Chang KS,Kantarjian H,Estey E

更新日期：2001-01-01 00:00:00

abstract：:Imatinib is usually a highly effective treatment for myeloproliferative neoplasms (MPNs) associated with ABL, PDGFRA or PDGFRB gene fusions; however, occasional imatinib-responsive patients have been reported without abnormalities of these genes. To identify novel imatinib-sensitive lesions, we screened 11 BCR-ABL-neg...

journal_title：Leukemia

authors： Chase A,Schultheis B,Kreil S,Baxter J,Hidalgo-Curtis C,Jones A,Zhang L,Grand FH,Melo JV,Cross NC

更新日期：2009-02-01 00:00:00

abstract：:Despite the presence of tumor antigens, the paucity of clinically significant T-cell mediated immune responses against human tumors is striking. This may, in part, be because of the inability of cancer cells to function as efficient antigen-presenting cells. For full activation, T cells must receive two signals delive...

journal_title：Leukemia

authors： Gribben JG,Cardoso AA,Schultze JL,Nadler LM

更新日期：1997-05-01 00:00:00

abstract：:The effects of retinoic acid (RA) on the cell growth and expression of interleukin-2 (IL-2) receptors (IL-2R alpha/p55, Tac, CD25) by the human T lymphotropic virus type I (HTLV-I)-positive T cell lines, HUT102 and ATL-2 were investigated. Incubation of these cells for 48 h with either 13-cis retinoid acid (13-cis RA)...

journal_title：Leukemia

authors： Miyatake JI,Maeda Y

更新日期：1997-03-01 00:00:00

abstract：:ATP-binding-cassette (ABC) transporters are evolutionary extremely well-conserved transmembrane proteins that are highly expressed in hematopoietic stem cells (HSCs). The physiological function in human stem cells is believed to be protection against genetic damage caused by both environmental and naturally occurring ...

journal_title：Leukemia

authors： Raaijmakers MH

更新日期：2007-10-01 00:00:00

abstract：:Patients with hairy cell leukemia (HCL) are prone to opportunistic infections, which suggests an impaired T-cell functioning. To investigate a possible mechanism of such an impairment, we determined the numbers of naive and memory T cells by measuring the expression of CD45R0 on CD4+ and CD8+ T cells in 23 HCL patient...

journal_title：Leukemia

authors： van der Horst FA,van der Marel A,den Ottolander GJ,Kluin-Nelemans HC

更新日期：1993-01-01 00:00:00

abstract：:CDCP1, a novel stem cell marker, is expressed in hematopoietic cell line K562 but not in Jurkat. When CDCP1 promoter was transfected exogenously, Jurkat showed comparable promoter activity with K562, suggesting that the factor to enhance transcription was present but interfered to function in Jurkat. The reporter assa...

journal_title：Leukemia

authors： Kimura H,Morii E,Ikeda JI,Ezoe S,Xu JX,Nakamichi N,Tomita Y,Shibayama H,Kanakura Y,Aozasa K

更新日期：2006-09-01 00:00:00

abstract：:All-trans retinoic acid has recently been shown to induce differentiation of acute promyelocytic leukemia cells in vitro and in vivo. Clinical trials of patients treated de novo, in first relapse, and with resistant disease have achieved a high rate of complete remission (CR). The overall toxicity is substantially les...

journal_title：Leukemia

authors： Vosburgh E

更新日期：1992-06-01 00:00:00

abstract：:Outcomes for patients with multiple myeloma (MM) have improved in recent years owing to use of novel agents and high-dose therapy followed by autologous stem cell transplant (ASCT). We analyzed the outcomes of 511 consecutive patients treated with novel therapies at our institution between 2006 and 2014 to determine t...

journal_title：Leukemia

authors： Majithia N,Rajkumar SV,Lacy MQ,Buadi FK,Dispenzieri A,Gertz MA,Hayman SR,Dingli D,Kapoor P,Hwa L,Lust JA,Russell SJ,Go RS,Kyle RA,Kumar SK

更新日期：2016-11-01 00:00:00

abstract：:The lens epithelium-derived growth factor (LEDGF/p75) tethers the mixed-lineage leukemia (MLL1) protein complex to chromatin. Likewise, LEDGF/p75 tethers the HIV-1 pre-integration complex to chromatin. We previously demonstrated that expression of the C-terminal fragment fused to enhanced green fluorescent protein (eG...

journal_title：Leukemia

authors： Méreau H,De Rijck J,Cermáková K,Kutz A,Juge S,Demeulemeester J,Gijsbers R,Christ F,Debyser Z,Schwaller J

更新日期：2013-06-01 00:00:00

abstract：:P38α/β has been described as a tumor-suppressor controlling cell cycle checkpoints and senescence in epithelial malignancies. However, p38α/β also regulates other cellular processes. Here, we describe a role of p38α/β as a regulator of acute lymphoblastic leukemia (ALL) proliferation and survival in experimental ALL m...

journal_title：Leukemia

authors： Alsadeq A,Strube S,Krause S,Carlet M,Jeremias I,Vokuhl C,Loges S,Aguirre-Ghiso JA,Trauzold A,Cario G,Stanulla M,Schrappe M,Schewe DM

更新日期：2015-12-01 00:00:00

abstract：:Many agents have been known to induce the differentiation of HL-60 cells. However, only a small number of reports on the basophilic differentiation of this cell line are known. In this study we show that the exposure of HL-60 cells to chloroquine induces to differentiate into basophils. This chloroquine-induced change...

journal_title：Leukemia

authors： Sasaki R,Furukawa Y,Okada K,Nakamura M,Yamane Y,Miura Y,Eguchi M

更新日期：1997-04-01 00:00:00

abstract：:Children with acute lymphoblastic leukemia (ALL) with > or = 0.01% leukemic cells in the bone marrow after remission induction are at a greater risk of relapse. The most promising methods of detecting minimal residual disease (MRD) are flow cytometric identification of leukemia-associated immunophenotypes and polymera...

journal_title：Leukemia

authors： Neale GA,Coustan-Smith E,Pan Q,Chen X,Gruhn B,Stow P,Behm FG,Pui CH,Campana D

更新日期：1999-08-01 00:00:00

abstract：:Bortezomib is a potent drug for the treatment of multiple myeloma. Its anti-tumor activity is mediated by proteasome inhibition leading to decreased cell proliferation and induction of apoptosis. However, an unimpaired proteasomal function plays a crucial role for the induction of anti-tumor immunity by dendritic cell...

journal_title：Leukemia

authors： Straube C,Wehner R,Wendisch M,Bornhäuser M,Bachmann M,Rieber EP,Schmitz M

更新日期：2007-07-01 00:00:00